Stock listing
Frankfurt:2OK SpectraCure AB Aktie
German listing (Frankfurt) of SpectraCure AB · home listing Stockholm:SPEC
Follow SpectraCure AB into a list and get an email when it puts out news.
Share price · FWB:2OK
€0.0010 EUR
Close on Nov 20, 2026
- Day range
- €0.0010 – €0.0010 EURNov 20, 2026
- Market cap
- €735,490 EURAt the close on Nov 20, 2026 · price × 735.5M shares outstanding
- 52-week range
- €0.0010 – €0.0060 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:SPEC · Home | 0.014 SEK | +0.001 (+7.9%) | 5,100,036 | 0.012 | 0.014 | 0.012 | 0.013 | Close on Nov 20, 2026 |
| Frankfurt:2OK | €0.0010 EUR | — | — | €0.0010 | €0.0010 | €0.0010 | — | Close on Nov 20, 2026 |
- Ticker
- Frankfurt:2OK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Jun 1, 2026
Spectracure Appoints Fata Mrsic As CFO
Latest news
Spectracure Appoints Fata Mrsic As CFO
Jun 1, 2026
Closed €0.0030 (+50.0%) on Jun 1, 2026
Spectracure Q1 Net Loss After Tax SEK 6.1 Mln
May 27, 2026
Closed €0.0020 (+100.0%) on May 29, 2026
SpectraCure AB on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 5 in the last 12 months · 24 in all · newest Jun 1, 2026 · oldest 2020
- Decks
- 3 decks · latest December 2024
Where SpectraCure AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:SPEC · Home listing | Stockholm | Sweden | SEK |
| Frankfurt:2OK · This page | Frankfurt | Germany | EUR |
Valuation
EV/sales 32.1× against a median of 0.2×: the highest of 7 Medical devices & supplies companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 11.28M SEK
- P/E
- Loss
- EV/sales
- 32.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| SpectraCure AB · OMXSTO:SPEC | US$981,033 | US$1.11M | n/a | 32.1× | n/a | 0.1× | n/a | 0.1× | n/a |
| Nuwellis, Inc. · NASDAQ:NUWE | US$1.84M | −US$6.31M | n/a | −0.7× | n/a | 0.2× | −152.8% | 0.0× | 2.26 |
| Vivos Therapeutics, Inc. · NASDAQ:VVOS | US$1.83M | US$2.11M | n/a | 0.1× | n/a | 0.8× | −107.1% | 0.2× | 1.41 |
| Autonomix Medical, Inc. · NASDAQ:AMIX | US$1.82M | −US$5.87M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.79 |
| Adagio Medical Holdings, Inc · NASDAQ:ADGM | US$1.72M | US$636,010 | 2.1× | n/a | n/a | 0.1× | n/a | 0.1× | 0.69 |
| Escalon Medical Corp. · OTC:ESMC | US$1.71M | −US$1.96M | 0.4× | −0.1× | n/a | 0.3× | 32.8% | 0.0× | -0.06 |
| Therma Bright Inc. · TSXV:THRM | US$1.66M | US$1.64M | n/a | 17.3× | n/a | n/a | n/a | n/a | -0.15 |
| Nexalin Technology, Inc. · NASDAQ:NXL | US$1.45M | US$1.88M | n/a | 6.8× | n/a | 5.5× | n/a | 4.7× | 0.52 |
| Zero Candida Technologies Inc. · TSXV:ZCT | US$1.43M | −US$59,297 | n/a | n/a | n/a | 2.2× | n/a | 0.0× | -0.17 |
| Osteopore Ltd. · ASX:OSX | US$1.38M | US$596,514 | n/a | 0.3× | n/a | n/a | −121.8% | n/a | n/a |
| Odyssey Health Inc. · OTC:ODYY | US$716,421 | US$594,060 | n/a | n/a | n/a | n/a | n/a | n/a | 0.58 |
| Median of the others | US$1.68M | US$595,287 | 1.2× | 0.2× | 0.3× | −114.5% | 0.0× | 0.58 |
Team and board
| Director | Role |
|---|---|
| Jörgen Wennberg | Chairman of the Board |
| Jesper Freij | Board member |
| Masoud Khayyami | Board member |
| Patrik Ringblom | Board member |
| Stefan Andersson-Engels | Board member |
| Tomas Kramar | Board member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | −3.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2024) | Investor deck | 23 slides | December 2024 |
| Shareholder Meeting (May 2022) | Shareholder meeting | 12 slides | May 12, 2022 |
| Shareholder Meeting (May 2022) | Shareholder meeting | 11 slides | May 12, 2022 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of rights issue Closed: SEK 54.8M raised Use of proceeds: To support ongoing clinical trials | Aug 15, 2025 | US$5.74M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 868.0K | 19.5M | 318.0K | 539.0K | 5.75M | 1.21K | 763 | 596.0K | 259.0K | 172.9K |
| Cost of revenue | 30.1M | 9.77M | 9.54M | -3.05M | -1.39M | -2.35M | -2.62M | -2.13M | -1.55M | -1.14M |
| Gross profit | -30.1M | 9.77M | -9.22M | 3.58M | 1.39M | 2.35M | 2.62M | 2.72M | 1.81M | 1.31M |
| Selling, general and administrative | 13.4M | 12.3M | 12.7M | 11.6M | 10.7M | 8.32M | 7.82M | 6.55M | 5.93M | 5.21M |
| Operating income | -54.4M | -24.5M | -21.4M | -27.0M | -24.4M | -16.5M | -14.3M | -9.62M | -8.70M | -6.82M |
| Depreciation and amortization | 2.55M | 2.63M | 2.66M | 2.93M | 2.67M | 2.28M | 2.12M | 150.0K | 1.17M | 136.8K |
| EBITDA | -51.8M | -21.9M | -18.7M | -24.0M | -21.8M | -14.2M | -12.2M | -9.47M | -7.53M | -6.68M |
| Interest expense | 1.25M | 468.0K | 522.0K | 182.0K | 245.0K | 276.0K | 224.0K | 0 | 64 | 43.5K |
| Income before tax | -56.1M | -23.0M | -20.5M | -25.4M | -23.3M | -15.4M | -13.7M | -9.61M | -8.70M | -6.37M |
| Income tax | 27.0K | -7.00K | -21.0K | -53.0K | -5.00K | -30.0K | -7.00K | 167.0K | 51 | 550 |
| Net income | -56.1M | -23.0M | -20.4M | -25.3M | -23.3M | -15.4M | -13.7M | -9.61M | -8.70M | -6.37M |
| Earnings per share, basic | -0.14 | -0.24 | -0.21 | -0.26 | -0.24 | -0.17 | -0.16 | -0.12 | -0.15 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 13.5M | 18.3M | 57.0M | 93.2M | 129.7M | 157.2M | 54.2M | 45.1M | 2.44M | 381.7K |
| Receivables | 2.21M | 3.62M | 183.0K | 1.10M | 1.08M | 872.0K | 842.0K | 1.80M | 249.5K | 19.6M |
| Inventory | 1 | 0 | -1 | 0 | 0 | -13.0K | -4.40K | -19.2M | ||
| Current assets | 16.2M | 22.2M | 58.7M | 94.3M | 130.8M | 158.4M | 56.8M | 47.5M | 2.91M | 20.0M |
| Property, plant and equipment | 3.05M | 5.40M | 6.95M | 3.96M | 6.18M | 6.71M | 7.99M | 132.0K | 193.7K | 121.1K |
| Total assets | 104.5M | 121.0M | 144.8M | 162.4M | 190.5M | 210.5M | 100.2M | 68.9M | 14.7M | 28.8M |
| Accounts payable | 1.71M | 3.32M | 1.04M | 1.61M | 1.83M | 59.0K | 1.75M | 1.56M | 391.7K | 3.04M |
| Current liabilities | 10.7M | 11.5M | 10.6M | 11.8M | 12.4M | 9.86M | 7.55M | 4.03M | 1.30M | 6.66M |
| Total debt | 3.01M | 5.14M | 6.72M | 2.70M | 4.90M | 5.36M | 6.71M | |||
| Total liabilities | 10.9M | 14.1M | 15.0M | 12.1M | 14.8M | 13.3M | 12.4M | 4.03M | 1.30M | 6.66M |
| Shareholders' equity | 93.5M | 106.9M | 129.9M | 150.3M | 175.7M | 197.2M | 87.8M | 64.9M | 13.4M | 22.1M |
| Shares outstanding | 409.7M | 97.1M | 97.1M | 97.1M | 97.1M | 92.4M | 83.1M | 78.4M | 57.1M | 30.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24.0M | -21.8M | -18.7M | -23.0M | -18.6M | -9.40M | -10.1M | -8.97M | 6.33M | -19.6M |
| Capital spending | -19.6M | -15.3M | -15.8M | -10.1M | -8.49M | -10.6M | -15.1M | -9.39M | -4.27M | -3.80M |
| Free cash flow | -43.7M | -37.1M | -34.4M | -33.1M | -27.1M | -20.0M | -25.2M | -18.4M | 2.06M | -23.4M |
| Cash from investing | -19.6M | -15.3M | -15.6M | -11.3M | -8.49M | -10.6M | -15.1M | -9.39M | -4.27M | -3.62M |
| Cash from financing | 38.9M | -1.57M | -1.99M | -2.20M | -453.0K | 123.0M | 34.3M | 50.6M | 67.5M | 15.4M |
| Share buybacks | 54.8M | 0 | 139.9M | 37.9M | 57.6M | 0 | 15.4M | |||
| Change in cash | -4.75M | -38.7M | -36.2M | -36.5M | -27.5M | 103.0M | 9.13M | 32.2M | 2.06M | -7.79M |
Cap table
Built by 6ix from SpectraCure AB’s releases · as of Aug 15, 2025
- Common shares
- 735,491,879
- Fully diluted
- 735,491,879
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 735,491,879 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 735,491,879 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jesper Freij | Board member · Since at least Nov 5, 2026 |
| Jörgen Wennberg | Chairman of the Board · Since at least Nov 5, 2026 |
| Masoud Khayyami | Board member · Since at least Oct 1, 2025 |
| Patrik Ringblom | Board member · Since at least Nov 5, 2026 |
| Stefan Andersson-Engels | Board member · Since at least Nov 5, 2026 |
| Tomas Kramar | Board member · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about SpectraCure AB.